Retatrutide vs Semaglutide: research-use price per mg, identity and FDA status (2026)
Retatrutide and Semaglutide are different research compounds, not substitutes for each other: Retatrutide is a single compound (C221H342N46O68); Semaglutide is a single compound (C187H291N45O59). Lowest current research-use listings: Retatrutide 30mg from $199.99 ($6.67/mg) at Amino Club; Semaglutide 10mg from $49.99 ($5.00/mg) at Amino Club. Retatrutide has no Drugs@FDA application; Semaglutide shares its active ingredient with an FDA-approved prescription medicine.
Research use only. These are research-use-only listings sold for laboratory research, not prescription medicines and not for human use. PeptideTech does not compare effects or provide dosing information.
Retatrutide vs Semaglutide: current prices and packages
| Compared property | Retatrutide | Semaglutide |
|---|---|---|
| Category | GLP-1 | GLP-1 |
| Compared package | 30mg · Vial | 10mg · Vial |
| Lowest current price | $199.99 at Amino Club, checked Oct 14, 2026 | $49.99 at Amino Club, checked Oct 14, 2026 |
| Price per labelled mg | $6.67/mg | $5.00/mg |
| Package sizes | 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 48mg, 50mg, 60mg | 5mg, 10mg, 15mg, 20mg, 30mg, 50mg |
| Vendors with current prices | 2 (3 tracked) | 3 (4 tracked) |
| Form at this package | Vial | Vial |
| Stock | In stock | In stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | Retatrutide | Semaglutide |
|---|---|---|
| Molecular formula | C221H342N46O68 | C187H291N45O59 |
| Molecular weight | 4731 g/mol | 4114 g/mol |
| Sequence | — | — |
| CAS Registry Number | — | 910463-68-2 |
| Registered clinical trials | 34 (11 active) · Phase 3: 14, Phase 2: 4, Phase 1: 15 | 34 (34 active) · Phase 4: 8, Phase 3: 12, Phase 2: 2 |
| Human intervention studies | 7 | 5 |
| US regulatory status | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search | FDA-approved prescription medicine with this active ingredient: Ozempic, Rybelsus and Wegovy (NDA 209637, NDA 213051, NDA 213182, NDA 215256 and NDA 218316; checked October 7, 2026)MarketedOZEMPIC · NDA 209637 · 2017OZEMPIC / RYBELSUS · NDA 213051 · 2019RYBELSUS · NDA 213182 · 2020WEGOVY · NDA 215256 · 2021WEGOVY · NDA 218316 · 2025Research listings are not these medicines. |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
Retatrutide
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 2024
Semaglutide
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism, 2022
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2021
Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Research-use listings for each compound
Research-use-only listings sold for laboratory research, not prescription medicines and not for human use.
Retatrutide
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence.
$199.99 · 30mg · $6.67/mg · Amino Club
View at Amino Club, Retatrutide 30mg, opens in a new tabPeptideTech does not sell or fulfill products. Some outgoing links can earn a commission, which does not determine price order. How we rankRetatrutide prices →Price history →Semaglutide
Semaglutide is a GLP-1 receptor agonist and the active substance in the EU-authorized prescription medicine Wegovy. Evidence and authorization attach to specified medicinal products and their studied use.
$49.99 · 10mg · $5.00/mg · Amino Club
View at Amino Club, Semaglutide 10mg, opens in a new tabPeptideTech does not sell or fulfill products. Some outgoing links can earn a commission, which does not determine price order. How we rankSemaglutide prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price only. PeptideTech earns a commission when you buy through a link; it never changes the order.
Full method →